CHD1-Deficiency Engenders a Distinct Epigenetic Profile in Castration-Resistant Prostate Cancer
Abstract
This proposal addresses specific gaps in prostate cancer research and treatment by addressing two overarching challenges: 1) Developing treatments that improve outcomes for men with lethal prostate cancer and 2) Defining the biology of lethal prostate cancer to reduce death. Recent data highlights an important role for epigenetic dysregulation in CRPC cells. This proposal can potentially define an aspect of the biology underlying lethal prostate cancer which can lead to fewer annual deaths from this disease. Furthermore, epigenetic enzyme dysregulation represents a therapeutic target. However, knowing how these changes are driven represents a significant barrier to improved therapies. The research proposed here addresses this knowledge gap so that next-generation CRPC treatments can be developed to improve outcomes for men with lethal prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1127514
Entities
People
- David F Jarrard
- Joseph Gawdzik
Organizations
- University of Wisconsin System